JOSÉ LUIS PEDRAZ MUÑOZ-rekin lankidetzan egindako argitalpenak (29)

2011

  1. Novel extended-release formulation of lovastatin by one-step melt granulation: In vitro and in vivo evaluation

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 77, Núm. 2, pp. 306-312

2010

  1. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: Level A in vitro-in vivo correlation

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 75, Núm. 2, pp. 232-237

  2. Solid lipid nanoparticles as potential tools for gene therapy: In vivo protein expression after intravenous administration

    International Journal of Pharmaceutics, Vol. 385, Núm. 1-2, pp. 157-162

2009

  1. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors

    Journal of Controlled Release, Vol. 133, Núm. 1, pp. 52-59

  2. Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 71, Núm. 2, pp. 181-189

2008

  1. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy

    Clinical Pharmacokinetics, Vol. 47, Núm. 3, pp. 173-180

  2. Solid lipid nanoparticles for retinal gene therapy: Transfection and intracellular trafficking in RPE cells

    International Journal of Pharmaceutics, Vol. 360, Núm. 1-2, pp. 177-183

2007

  1. Solid lipid nanoparticles: Formulation factors affecting cell transfection capacity

    International Journal of Pharmaceutics, Vol. 339, Núm. 1-2, pp. 261-268

2006

  1. Terapia génica: concepto, sistemas de administración y aplicaciones

    Industria farmacéutica: Equipos, procesos y tecnología, Núm. 128, pp. 86-99

2005

  1. Análisis farmacocinético/farmacodinámico (PK/PD) de la antibioterapia en odontoestomatología

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 23, Núm. 3, pp. 116-121

  2. Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 39, Núm. 5, pp. 996-1005

  3. Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections

    Clinical Pharmacokinetics, Vol. 44, Núm. 3, pp. 305-316

  4. Quantification and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC

    Biomedical Chromatography, Vol. 19, Núm. 8, pp. 570-578

2004

  1. Bioequivalence of two oral ciprofloxacin tablets formulations

    International Journal of Clinical Pharmacology and Therapeutics, Vol. 42, Núm. 6, pp. 336-341

2003

  1. Comparative bioavailability of two immediate-release tablets of lisinopril/hydrochlorothiazide in healthy volunteers

    International Journal of Clinical Pharmacology and Therapeutics, Vol. 41, Núm. 7, pp. 309-315

  2. In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations

    Arzneimittel-Forschung/Drug Research, Vol. 53, Núm. 5, pp. 321-329

  3. Release of salbutamol enantiomers from HPMC matrices elaborated by wetgranulation

    Congreso de la SEFIG (4º. Granada. 2003). 3as. Jornadas de Tecnología Farmacéutica

2002

  1. Release of ketoprofen enantiomers from HPMC K100M matrices - Diffusion studies

    International Journal of Pharmaceutics, Vol. 239, Núm. 1-2, pp. 61-68

  2. Release of salbutamol sulphate and ketoprofen enantiomers from matrices containing HPMC and cellulose derivatives

    Chirality, Vol. 14, Núm. 10, pp. 806-813

  3. Stereoselective release of ketoprofen from matrices containing cellulose derivatives

    World Meeting ADRITELF/APGI/APV (4th. Florencia. 2002)